Esophageal and Gastric Cancer Pearl: a nationwide clinical biobanking project in the Netherlands

L. Haverkamp; K. Parry; M. I. van Berge Henegouwen; H. W. van Laarhoven; J. J. Bonenkamp; T. M. Bisseling; P. D. Siersema; M. N. Sosef; J.H. Stoot; G. L. Beets; W. O. de Steur; H. H. Hartgrink; H. W. Verspaget; D. L. van der Peet; J. T. Plukker; B. van Etten; B.P.L. Wijnhoven; J. J. van Lanschot; R. van Hillegersberg; J. P. Ruurda

doi:10.1111/dote.12347

Esophageal and Gastric Cancer Pearl: a nationwide clinical biobanking project in the Netherlands

L. Haverkamp, K. Parry, M. I. van Berge Henegouwen, H. W. van Laarhoven, J. J. Bonenkamp, T. M. Bisseling, P. D. Siersema, M. N. Sosef, J.H. Stoot, G. L. Beets, W. O. de Steur, H. H. Hartgrink, H. W. Verspaget, D. L. van der Peet, J. T. Plukker, B. van Etten, B.P.L. Wijnhoven, J. J. van Lanschot, R. van Hillegersberg, J. P. Ruurda^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Esophageal and gastric cancer is associated with a poor prognosis since many patients develop recurrent disease. Treatment requires specific expertise and a structured multidisciplinary approach. In the Netherlands, this type of expertise is mainly found at the University Medical Centers (UMCs) and a few specialized nonacademic centers. Aim of this study is to implement a national infrastructure for research to gain more insight in the etiology and prognosis of esophageal and gastric cancer and to evaluate and improve the response on (neoadjuvant) treatment. Clinical data are collected in a prospective database, which is linked to the patients' biomaterial. The collection and storage of biomaterial is performed according to standard operating procedures in all participating UMCs as established within the Parelsnoer Institute. The collected biomaterial consists of tumor biopsies, blood samples, samples of malignant and healthy tissue of the resected specimen and biopsies of recurrence. The collected material is stored in the local biobanks and is encoded to respect the privacy of the donors. After approval of the study was obtained from the Institutional Review Board, the first patient was included in October 2014. The target aim is to include 300 patients annually. In conclusion, the eight UMCs of the Netherlands collaborated to establish a nationwide database of clinical information and biomaterial of patients with esophageal and gastric cancer. Due to the national coverage, a high number of patients are expected to be included. This will provide opportunity for future studies to gain more insight in the etiology, treatment and prognosis of esophageal and gastric cancer.

Original language	English
Pages (from-to)	435-441
Journal	Diseases of the Esophagus
Volume	29
Issue number	5
DOIs	https://doi.org/10.1111/dote.12347
Publication status	Published - Jul 2016

Keywords

biobanking
esophageal and gastric cancer
the Netherlands

Access to Document

10.1111/dote.12347Licence: Other

Cite this

Haverkamp, L., Parry, K., Henegouwen, M. I. V. B., van Laarhoven, H. W., Bonenkamp, J. J., Bisseling, T. M., Siersema, P. D., Sosef, M. N., Stoot, J. H., Beets, G. L., de Steur, W. O., Hartgrink, H. H., Verspaget, H. W., van der Peet, D. L., Plukker, J. T., van Etten, B., Wijnhoven, B. P. L., van Lanschot, J. J., van Hillegersberg, R., & Ruurda, J. P. (2016). Esophageal and Gastric Cancer Pearl: a nationwide clinical biobanking project in the Netherlands. Diseases of the Esophagus, 29(5), 435-441. https://doi.org/10.1111/dote.12347

@article{7dc5e875c6dc4430b4a88d59ae9c0866,

title = "Esophageal and Gastric Cancer Pearl: a nationwide clinical biobanking project in the Netherlands",

abstract = "Esophageal and gastric cancer is associated with a poor prognosis since many patients develop recurrent disease. Treatment requires specific expertise and a structured multidisciplinary approach. In the Netherlands, this type of expertise is mainly found at the University Medical Centers (UMCs) and a few specialized nonacademic centers. Aim of this study is to implement a national infrastructure for research to gain more insight in the etiology and prognosis of esophageal and gastric cancer and to evaluate and improve the response on (neoadjuvant) treatment. Clinical data are collected in a prospective database, which is linked to the patients' biomaterial. The collection and storage of biomaterial is performed according to standard operating procedures in all participating UMCs as established within the Parelsnoer Institute. The collected biomaterial consists of tumor biopsies, blood samples, samples of malignant and healthy tissue of the resected specimen and biopsies of recurrence. The collected material is stored in the local biobanks and is encoded to respect the privacy of the donors. After approval of the study was obtained from the Institutional Review Board, the first patient was included in October 2014. The target aim is to include 300 patients annually. In conclusion, the eight UMCs of the Netherlands collaborated to establish a nationwide database of clinical information and biomaterial of patients with esophageal and gastric cancer. Due to the national coverage, a high number of patients are expected to be included. This will provide opportunity for future studies to gain more insight in the etiology, treatment and prognosis of esophageal and gastric cancer.",

keywords = "biobanking, esophageal and gastric cancer, the Netherlands",

author = "L. Haverkamp and K. Parry and Henegouwen, {M. I. van Berge} and {van Laarhoven}, {H. W.} and Bonenkamp, {J. J.} and Bisseling, {T. M.} and Siersema, {P. D.} and Sosef, {M. N.} and J.H. Stoot and Beets, {G. L.} and {de Steur}, {W. O.} and Hartgrink, {H. H.} and Verspaget, {H. W.} and {van der Peet}, {D. L.} and Plukker, {J. T.} and {van Etten}, B. and B.P.L. Wijnhoven and {van Lanschot}, {J. J.} and {van Hillegersberg}, R. and Ruurda, {J. P.}",

year = "2016",

month = jul,

doi = "10.1111/dote.12347",

language = "English",

volume = "29",

pages = "435--441",

journal = "Diseases of the Esophagus",

issn = "1120-8694",

publisher = "Wiley-Blackwell",

number = "5",

}

Haverkamp, L, Parry, K, Henegouwen, MIVB, van Laarhoven, HW, Bonenkamp, JJ, Bisseling, TM, Siersema, PD, Sosef, MN, Stoot, JH, Beets, GL, de Steur, WO, Hartgrink, HH, Verspaget, HW, van der Peet, DL, Plukker, JT, van Etten, B, Wijnhoven, BPL, van Lanschot, JJ, van Hillegersberg, R & Ruurda, JP 2016, 'Esophageal and Gastric Cancer Pearl: a nationwide clinical biobanking project in the Netherlands', Diseases of the Esophagus, vol. 29, no. 5, pp. 435-441. https://doi.org/10.1111/dote.12347

TY - JOUR

T1 - Esophageal and Gastric Cancer Pearl: a nationwide clinical biobanking project in the Netherlands

AU - Haverkamp, L.

AU - Parry, K.

AU - Henegouwen, M. I. van Berge

AU - van Laarhoven, H. W.

AU - Bonenkamp, J. J.

AU - Bisseling, T. M.

AU - Siersema, P. D.

AU - Sosef, M. N.

AU - Stoot, J.H.

AU - Beets, G. L.

AU - de Steur, W. O.

AU - Hartgrink, H. H.

AU - Verspaget, H. W.

AU - van der Peet, D. L.

AU - Plukker, J. T.

AU - van Etten, B.

AU - Wijnhoven, B.P.L.

AU - van Lanschot, J. J.

AU - van Hillegersberg, R.

AU - Ruurda, J. P.

PY - 2016/7

Y1 - 2016/7

N2 - Esophageal and gastric cancer is associated with a poor prognosis since many patients develop recurrent disease. Treatment requires specific expertise and a structured multidisciplinary approach. In the Netherlands, this type of expertise is mainly found at the University Medical Centers (UMCs) and a few specialized nonacademic centers. Aim of this study is to implement a national infrastructure for research to gain more insight in the etiology and prognosis of esophageal and gastric cancer and to evaluate and improve the response on (neoadjuvant) treatment. Clinical data are collected in a prospective database, which is linked to the patients' biomaterial. The collection and storage of biomaterial is performed according to standard operating procedures in all participating UMCs as established within the Parelsnoer Institute. The collected biomaterial consists of tumor biopsies, blood samples, samples of malignant and healthy tissue of the resected specimen and biopsies of recurrence. The collected material is stored in the local biobanks and is encoded to respect the privacy of the donors. After approval of the study was obtained from the Institutional Review Board, the first patient was included in October 2014. The target aim is to include 300 patients annually. In conclusion, the eight UMCs of the Netherlands collaborated to establish a nationwide database of clinical information and biomaterial of patients with esophageal and gastric cancer. Due to the national coverage, a high number of patients are expected to be included. This will provide opportunity for future studies to gain more insight in the etiology, treatment and prognosis of esophageal and gastric cancer.

AB - Esophageal and gastric cancer is associated with a poor prognosis since many patients develop recurrent disease. Treatment requires specific expertise and a structured multidisciplinary approach. In the Netherlands, this type of expertise is mainly found at the University Medical Centers (UMCs) and a few specialized nonacademic centers. Aim of this study is to implement a national infrastructure for research to gain more insight in the etiology and prognosis of esophageal and gastric cancer and to evaluate and improve the response on (neoadjuvant) treatment. Clinical data are collected in a prospective database, which is linked to the patients' biomaterial. The collection and storage of biomaterial is performed according to standard operating procedures in all participating UMCs as established within the Parelsnoer Institute. The collected biomaterial consists of tumor biopsies, blood samples, samples of malignant and healthy tissue of the resected specimen and biopsies of recurrence. The collected material is stored in the local biobanks and is encoded to respect the privacy of the donors. After approval of the study was obtained from the Institutional Review Board, the first patient was included in October 2014. The target aim is to include 300 patients annually. In conclusion, the eight UMCs of the Netherlands collaborated to establish a nationwide database of clinical information and biomaterial of patients with esophageal and gastric cancer. Due to the national coverage, a high number of patients are expected to be included. This will provide opportunity for future studies to gain more insight in the etiology, treatment and prognosis of esophageal and gastric cancer.

KW - biobanking

KW - esophageal and gastric cancer

KW - the Netherlands

U2 - 10.1111/dote.12347

DO - 10.1111/dote.12347

M3 - Article

C2 - 25824294

SN - 1120-8694

VL - 29

SP - 435

EP - 441

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

IS - 5

ER -